Fund Evaluator:
Innovator Eq Dual Drctnl 15 Buf ETFOct (DDFO)
Follow This Fund
Equity
Global Asset Class
Nontraditional Equity
Fund Group
Defined Outcome
Category
$0.000
NAV (as of )
$0.00
Minimum Initial
0.79% B
Expense Ratio
$100 Mil
Assets
Open
Status
0.00%
12b-1 Fee
na
TTM Yield
0.00%
Max Load
na
Portfolio Turnover
Best Performing in Defined Outcome Over the Last Year
| 13.0% | Vest US Large Cap 10% Buffer Strats Inv (BUMGX) |
| 8.6% | Vest US Large Cap 20% Buffer Strats Inv (ENGLX) |
Data as of 7/31/2026
0.6% C
1-Mo Return
2.1% D
3-Mo Return
4.8% D
YTD Return
na
1-Yr Return
na
3-Yr Return
na
5-Yr Return
na
Category Risk Index
na
Total Risk Index
Fund Details
Fund Family
Innovator ETFs
Inception Date
9/30/2025
Share Class Type
Equity Investment Style
Large-Cap
Blend
Bond Investment Style
na
Socially Responsible Fund
No
Index Fund
No
Benchmark Index
N/A: 100%
Additional Fund Details
Innovator Eq Dual Drctnl 15 Buf ETFOct Overview
DDFO Trailing NAV Total Returns Data as of 7/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| DDFO Return (NAV) | 0.6% | 2.1% | na | na | na | na |
| DDFO Grade | C | D | na | na | na | na |
| +/- Category | 0.2% | -0.3% | na | na | na | na |
| Defined Outcome Avg | 0.3% | 2.3% | 10.8% | 10.6% | 7.8% | na |
| DDFO Tax Cost Ratio | na | na | na | na | na | na |
DDFO Annual NAV Total ReturnsData as of 7/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| DDFO Return (NAV) | 4.8% | na | na | na | na | na | na | na | na | na | na |
| DDFO Grade | D | na | na | na | na | na | na | na | na | na | na |
| +/- Category | -0.8% | na | na | na | na | na | na | na | na | na | na |
| Defined Outcome Avg | 5.6% | 9.9% | 12.7% | 16.2% | -8.3% | 13.6% | 11.7% | 23.9% | -4.9% | 15.1% | na |
| Risk Measures | |
| Standard Deviation: | na |
| Total Risk Index: | na |
| Category Risk Index: | na |
| Category Risk Grade: | |
| Beta: | na |
| R-Squared: | na |
| Leveraged Fund: | No |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Large-Cap Blend |
| Bond Investment Style: | na |
| Yield: | -- |
| Dividend Distribution: | Annually |
| Cap Gains Distribution: | Annually |
| Total Assets: | $100 Mil |
| Fund Total Assets: | $ 100 Mil |
| Share Class Type: | |
| Portfolio Turnover: | na |
Management Team
| Number of Managers: 4 | |||
| Longest Tenure: 0.8 years | |||
| Average Tenure: 0.8 years | |||
| Managers (Year): Greco Jeff (2025), Schiopu Maria (2025), Cummings Robert (2025), Lipp Rebekah (2025) | |||
Portfolio Composition (as of 7/31/26)
| # of Holdings: | 5 |
| % in Top 10 Holdings: | 113.4% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 0.5% |
Portfolio Allocation |
|
| Domestic Stock: | 99.2% |
| Foreign Stock: | 0.5% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 0.3% |
Purchase Information
| Fund Family: | Innovator ETFs |
| Phone Number: | 800-208-5212 |
| Website: | www.innovatorfunds.com |
| Status: | Open |
| Inception Date: | September 30, 2025 |
| Min. Initial Purchase: | $ 0 |
| Min. Initial IRA Purchase: | $ 0 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | 0.00% |
Expenses and Fees | |
| Expense Ratio (%): | 0.79% ( Rating : Above Avg ) |
| Category Average Expense Ratio (%): | 1.20% |
| Share Class: | Innovator Eq Dual Drctnl 15 Buf ETFOct |
| Min. Subsequent Purchase: | $ 0 |
| Min. Subsequent IRA Purchase: | $ 0 |
Copyright 2026 American Association of Individual Investors and Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.